Literature DB >> 3691616

Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis.

D Overbosch1, J C van de Nes, E Groll, H W Diekmann, A M Polderman, H Mattie.   

Abstract

Two patients with cysticercosis received praziquantel (PZQ) 75 mg/kg/day orally together with 30 mg prednisone daily for 3 weeks. The first patient presented with grand-mal seizures, a pyramidal tract syndrome and subcutaneous cysticerci, and the other had internal hydrocephalus necessitating drainage. Serial plasma samples were taken after the first dose of PZQ. Lumbar CSF was obtained from the first patient and ventricular CSF from the second. Subcutaneous cysticerci were removed from the first patient. PZQ in the specimens was assayed by GLC. For distribution between plasma and CSF a rate constant of 4.9 h-1 for free PZQ, corresponding to a t1/2 of 8 min or less for the non-protein bound fraction was calculated for Patient 1. In the second patient the distribution was so rapid that the rate constant could not be calculated. The difference in distribution rate might have been due to use of different sampling times or to a time lag in the entry of PZQ between the ventricles and the lumbar sac. The rate constant for distribution of the drug between plasma and parasites was 1.4 h-1, corresponding to a t1/2 of 30 min or less. Thus PZQ penetrates rapidly into the CSF. It enters the parasite more slowly, although still more rapidly than the plasma half-life of PZQ (1-1 1/2 h).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691616     DOI: 10.1007/bf00637564

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Synthesis and properties of Praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes.

Authors:  J Seubert; R Pohlke; F Loebich
Journal:  Experientia       Date:  1977-08-15

2.  The relation between plasma and tissue concentrations of antibiotics. Description of a method.

Authors:  H Mattie; J J Hoogeterp; J Hermans
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

3.  Treatment of cysticercosis with praziquantel in Colombia.

Authors:  D Botero; S Castaño
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

4.  [Human cysticercosis and praziquantel: a survey of first clinical experiences (author's transl)].

Authors:  E Groll
Journal:  Bol Chil Parasitol       Date:  1981 Jan-Jun

5.  Therapy of parenchymal brain cysticercosis with praziquantel.

Authors:  J Sotelo; F Escobedo; J Rodriguez-Carbajal; B Torres; F Rubio-Donnadieu
Journal:  N Engl J Med       Date:  1984-04-19       Impact factor: 91.245

6.  Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice.

Authors:  M W Kunst; H Mattie
Journal:  Infection       Date:  1978       Impact factor: 3.553

7.  Cysticercosis cerebri. Review of 127 cases.

Authors:  G F McCormick; C S Zee; J Heiden
Journal:  Arch Neurol       Date:  1982-09

8.  Cerebral cysticercosis: treatment with praziquantel. Report of two cases.

Authors:  K Markwalder; K Hess; A Valavanis; F Witassek
Journal:  Am J Trop Med Hyg       Date:  1984-03       Impact factor: 2.345

9.  Praziquantel: a major advance in anthelminthic therapy.

Authors:  R D Pearson; R L Guerrant
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

10.  Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel.

Authors:  L D deGhetaldi; R M Norman; A W Douville
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

View more
  8 in total

1.  Clinical and radiographic response of fourth ventricle cysticercosis to praziquantel therapy.

Authors:  J Fandiño; C Botana; C Fandiño; D Rodriguez; J Gomez-Bueno
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 2.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

3.  Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen.

Authors:  H Jung; R Medina; N Castro; T Corona; J Sotelo
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Praziquantel treatment of porcine brain and muscle Taenia solium cysticercosis. 1. Radiological, physiological and histopathological studies.

Authors:  A Flisser; D Gonzalez; M Shkurovich; I Madrazo; D Correa; J Rodriguez-Carbajal; S Cohen; E Rodriguez-del-Rosal; M Collado; B Fernandez
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

Review 5.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 6.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 7.  Antiparasitic drugs in children.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 8.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.